Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 856877 | ISIN: JP3197800000 | Ticker-Symbol: OMR1
Stuttgart
13.02.26 | 21:55
26,000 Euro
0,00 % 0,000
1-Jahres-Chart
OMRON CORPORATION Chart 1 Jahr
5-Tage-Chart
OMRON CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
25,80026,40019:04
25,80026,40013.02.
PR Newswire
470 Leser
Artikel bewerten:
(2)

OMRON HEALTHCARE Co., Ltd.: OMRON Healthcare Exceeds 400M Blood Pressure Monitors Sold

- Reinforcing Commitment to Preventive Cardiovascular and Home Blood Pressure Monitoring -

KYOTO, Japan, Sept. 29, 2025 /PRNewswire/ -- OMRON HEALTHCARE Co., Ltd., a global leader in innovative medical equipment for preventive healthcare, announced that cumulative worldwide sales of OMRON blood pressure monitors (BPMs) have exceeded 400 million units. This landmark achievement underscores the company's longstanding commitment to extending healthy life expectancy by advancing home blood pressure monitoring and preventive cardiovascular care.

Logo:
https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202509195504/_prw_PI1fl_k2sj30Cw.png

Image:
https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202509195504/_prw_PI2fl_68Qw97R2.png

The journey began over half a century ago, with the launch of the first OMRON-branded BPM in 1973, when all blood pressure measurement was conducted at medical facilities. Nowadays, thanks to advances in technology, anyone can easily and accurately measure their own blood pressure at home, and OMRON Healthcare has continued to drive the evolution of blood pressure management to support preventive healthcare, including efforts to detect potentially life-threatening conditions such as atrial fibrillation (AFib) at an early stage.

As a new chapter begins, OMRON Healthcare's industry-leading devices and digital health platforms continue to transform daily monitoring into a powerful tool for the protection of global health. With distribution in over 130 countries and regions worldwide, OMRON Healthcare is committed to ensuring access to accurate, cost-effective home blood pressure monitors in emerging markets where preventive healthcare resources remain limited, working to reduce health disparities by enabling early detection and intervention in communities most at risk.

"Reaching 400 million units sold is more than a number -- it represents the trust that millions of people place in OMRON Healthcare to support their journey toward longer, healthier lives," said Ayumu Okada, President and CEO, OMRON HEALTHCARE Co., Ltd. "The quality and accuracy of OMRON blood pressure monitors are well recognized by healthcare professionals around the world. We remain dedicated to 'Going for ZERO' vision, aiming to eradicate cerebro-cardiovascular events globally by developing technologies that connect daily life and healthcare, empowering people everywhere to take preventive action. We will continue to promote innovative products, services, and educational efforts to raise awareness of hypertension risks -- not only for those already diagnosed, but also for those who may not yet realize they are at risk."

https://healthcare.omron.com/going-for-zero/400-million

Innovation for Preventive Care
Building on over 50 years of expertise, OMRON Healthcare continues to advance technology that transforms blood pressure monitors into essential preventive care devices, through innovations including:

- Connected digital health monitoring: Bluetooth-enabled devices integrate with the OMRON connect app, supporting trend visualization, family sharing, and physician oversight.

- AI-powered detection: Unique, FDA-cleared Intellisense AFib technology enables early recognition of atrial fibrillation during routine monitoring.

- Integrated measurement: Complete monitor combines blood pressure and ECG readings, seamlessly shareable with physicians via the OMRON connect app.

- Remote monitoring partnerships: OMRON's Digital Health Business continues to expand with the acquisition of new subsidiary Luscii, and strategic partnerships with international companies.

About OMRON Healthcare: https://kyodonewsprwire.jp/attach/202509195504-O1-1133eHlN.pdf

For more information, please visit:
Website: https://healthcare.omron.com/
LinkedIn: https://www.linkedin.com/company/omron-healthcare-co-ltd-/

Cision View original content:https://www.prnewswire.co.uk/news-releases/omron-healthcare-exceeds-400m-blood-pressure-monitors-sold-302569172.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.